Akers Biosciences Responds to Erroneous Earnings Call Press Release

Rhea-AI Summary

Akers Biosciences, Inc. (NASDAQ: AKER) clarified that a press release regarding an earnings call by Aker ASA was mistakenly issued under its name. This press release is unrelated to Akers Biosciences, which has not scheduled any earnings calls. The Company is currently investigating the cause of this error and reserves the right to take necessary actions once more information is obtained.

Positive

• None.

Negative

• Miscommunication regarding earnings call could lead to confusion among investors.
• The error may raise concerns about the Company's public relations management.

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005868/en/

FAQ

What was the mistake in the press release related to AKER?

Akers Biosciences clarified that a press release concerning an earnings call by Aker ASA was incorrectly issued under its name, which is unrelated to the Company.

Is Akers Biosciences holding any earnings calls?

No, Akers Biosciences has not scheduled any earnings calls.

What actions is Akers Biosciences considering regarding the press release error?

The Company is investigating how the error occurred and may pursue appropriate remedies based on the findings.